Nils Martin Malmsten

Corporate Officer/Principal at University of Uppsala

Health Technology

Consumer Services

Commercial Services

Profile

Nils Martin Malmsten is the founder of DermaGen AB (founded in 2004) and Sista versen 26366 AB (founded in 2009).
He held the title of Director at both companies.
Currently, he is a Professor at the University of Uppsala.
Previously, he worked as a Principal at The Royal Society of Chemistry and Astra Arcus AB.

Nils Martin Malmsten active positions

Companies	Position	Start
University of Uppsala	Corporate Officer/Principal	-

All active positions of Nils Martin Malmsten

Former positions of Nils Martin Malmsten

Companies	Position	End
Sista versen 26366 AB Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden.	Founder	-
Astra Arcus AB	Corporate Officer/Principal	-
The Royal Society of Chemistry The Royal Society of Chemistry Miscellaneous Commercial ServicesCommercial Services The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists.	Corporate Officer/Principal	-
DermaGen AB DermaGen AB Pharmaceuticals: MajorHealth Technology DermaGen AB develops drugs and medical devices. It focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. The company was founded on February 2, 2004 and is headquartered in Solna, Sweden.	Founder	-

See the detail of Nils Martin Malmsten's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Nils Martin Malmsten's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
DermaGen AB DermaGen AB Pharmaceuticals: MajorHealth Technology DermaGen AB develops drugs and medical devices. It focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. The company was founded on February 2, 2004 and is headquartered in Solna, Sweden.	Health Technology
Astra Arcus AB
The Royal Society of Chemistry The Royal Society of Chemistry Miscellaneous Commercial ServicesCommercial Services The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists.	Commercial Services
Sista versen 26366 AB Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden.	Health Technology

See company connections